These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22120020)

  • 1. A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis.
    Bacalini MG; Tavolaro S; Peragine N; Marinelli M; Santangelo S; Del Giudice I; Mauro FR; Di Maio V; Ricciardi MR; Caiafa P; Chiaretti S; Foà R; Guarini A; Reale A
    Exp Hematol; 2012 Mar; 40(3):197-206.e1. PubMed ID: 22120020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia.
    Raval A; Lucas DM; Matkovic JJ; Bennett KL; Liyanarachchi S; Young DC; Rassenti L; Kipps TJ; Grever MR; Byrd JC; Plass C
    J Clin Oncol; 2005 Jun; 23(17):3877-85. PubMed ID: 15809452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia.
    Herriott A; Tudhope SJ; Junge G; Rodrigues N; Patterson MJ; Woodhouse L; Lunec J; Hunter JE; Mulligan EA; Cole M; Allinson LM; Wallis JP; Marshall S; Wang E; Curtin NJ; Willmore E
    Oncotarget; 2015 Dec; 6(41):43978-91. PubMed ID: 26539646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP1-driven apoptosis in chronic lymphocytic leukemia.
    Diamantopoulos PT; Sofotasiou M; Papadopoulou V; Polonyfi K; Iliakis T; Viniou NA
    Biomed Res Int; 2014; 2014():106713. PubMed ID: 25161998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
    Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
    Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage.
    Stankovic T; Stewart GS; Fegan C; Biggs P; Last J; Byrd PJ; Keenan RD; Moss PA; Taylor AM
    Blood; 2002 Jan; 99(1):300-9. PubMed ID: 11756185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia.
    Lin K; Farahani M; Yang Y; Johnson GG; Oates M; Atherton M; Douglas A; Kalakonda N; Pettitt AR
    Br J Haematol; 2014 Nov; 167(3):346-55. PubMed ID: 25040181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP1 expression in pediatric central nervous system tumors.
    Barton VN; Donson AM; Kleinschmidt-DeMasters BK; Gore L; Liu AK; Foreman NK
    Pediatr Blood Cancer; 2009 Dec; 53(7):1227-30. PubMed ID: 19533660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.
    Zhu HJ; Liu L; Fan L; Zhang LN; Fang C; Zou ZJ; Li JY; Xu W
    Leuk Lymphoma; 2013 Dec; 54(12):2712-9. PubMed ID: 23517560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.
    te Raa GD; Moerland PD; Leeksma AC; Derks IA; Yigittop H; Laddach N; Loden-van Straaten M; Navrkalova V; Trbusek M; Luijks DM; Zenz T; Skowronska A; Hoogendoorn M; Stankovic T; van Oers MH; Eldering E; Kater AP
    Cell Death Dis; 2015 Aug; 6(8):e1852. PubMed ID: 26247737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-34a as part of the resistance network in chronic lymphocytic leukemia.
    Zenz T; Mohr J; Eldering E; Kater AP; Bühler A; Kienle D; Winkler D; Dürig J; van Oers MH; Mertens D; Döhner H; Stilgenbauer S
    Blood; 2009 Apr; 113(16):3801-8. PubMed ID: 18941118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia.
    Humphries LA; Godbersen JC; Danilova OV; Kaur P; Christensen BC; Danilov AV
    Br J Haematol; 2013 Dec; 163(5):590-602. PubMed ID: 24117128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different gene expression in immunoglobulin-mutated and immunoglobulin-unmutated forms of chronic lymphocytic leukemia.
    Ferrer A; Ollila J; Tobin G; Nagy B; Thunberg U; Aalto Y; Vihinen M; Vilpo J; Rosenquist R; Knuutila S
    Cancer Genet Cytogenet; 2004 Aug; 153(1):69-72. PubMed ID: 15325098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia.
    Palma M; Parker A; Hojjat-Farsangi M; Forster J; Kokhaei P; Hansson L; Osterborg A; Mellstedt H
    Exp Hematol; 2013 Jul; 41(7):615-26. PubMed ID: 23548418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia.
    Papakonstantinou N; Ntoufa S; Chartomatsidou E; Kotta K; Agathangelidis A; Giassafaki L; Karamanli T; Bele P; Moysiadis T; Baliakas P; Sutton LA; Stavroyianni N; Anagnostopoulos A; Makris AM; Ghia P; Rosenquist R; Stamatopoulos K
    Oncotarget; 2016 Jun; 7(24):35946-35959. PubMed ID: 27191993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promising anti-leukemic activity of atorvastatin.
    Żołnierczyk JD; Borowiak A; Hikisz P; Cebula-Obrzut B; Błoński JZ; Smolewski P; Robak T; Kiliańska ZM
    Oncol Rep; 2013 May; 29(5):2065-71. PubMed ID: 23440293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mantle cell lymphoma displays a homogenous methylation profile: a comparative analysis with chronic lymphocytic leukemia.
    Halldórsdóttir AM; Kanduri M; Marincevic M; Mansouri L; Isaksson A; Göransson H; Axelsson T; Agarwal P; Jernberg-Wiklund H; Stamatopoulos K; Sander B; Ehrencrona H; Rosenquist R
    Am J Hematol; 2012 Apr; 87(4):361-7. PubMed ID: 22374828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The miR-17∼92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes.
    Bomben R; Gobessi S; Dal Bo M; Volinia S; Marconi D; Tissino E; Benedetti D; Zucchetto A; Rossi D; Gaidano G; Del Poeta G; Laurenti L; Efremov DG; Gattei V
    Leukemia; 2012 Jul; 26(7):1584-93. PubMed ID: 22343732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70).
    Schade U; Bock O; Vornhusen S; Jäger A; Büsche G; Lehmann U; Kreipe H
    Hum Pathol; 2006 Sep; 37(9):1153-61. PubMed ID: 16938520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells.
    Steele AJ; Prentice AG; Hoffbrand AV; Yogashangary BC; Hart SM; Lowdell MW; Samuel ER; North JM; Nacheva EP; Chanalaris A; Kottaridis P; Cwynarski K; Wickremasinghe RG
    Blood; 2009 Aug; 114(6):1217-25. PubMed ID: 19515722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.